Cordis, a Cardinal Health company, has announced the full US launch of its Radial 360 portfolio, offering a complete range of products to facilitate the transradial approach (TRA) for interventional cardiology procedures. The transradial approach uses the radial artery in the wrist to access the arterial system, rather than the femoral artery in the groin.
In a press release, Cordis outlines how the launch marks the beginning of a global radial product portfolio rollout to reach cardiovascular patients worldwide. The portfolio consists of Rain Sheath, a transradial thin-walled introducer; Railway, a sheathless access system; RBL-TG and RBL-JK, universal shapes for the Infiniti and Super Torque Plus diagnostic catheters; and Zephyr, a vascular compression band.
According to the press release, transradial access in the wrist can offer fewer bleeding complications, faster post-procedure mobility, improved patient comfort, and faster patient discharge resulting in reduced in-hospital costs, compared to a femoral access approach. TRA use in the USA is currently estimated to be approximately 30% of overall percutaneous coronary interventions (PCI) and growing.
Kintur Sanghvi (Deborah Heart & Lung Center, New Jersey, USA), inventor of the Railway system, says: “The transradial approach has been an important advancement in how we treat coronary artery disease because of both the patient benefits, and the advantages realized by the hospital in terms of procedure flow and economics. We look to the industry to help us advance the tools available for this technique, which Cordis has done with the introduction of the RADIAL 360 portfolio. In my experience with the RAILWAY™ System, I see the clear advantage of downsizing the radial access by up to 2F, a benefit that I’m unable to achieve with anything else that’s currently on the market.”
The Railway system received CE Mark in March 2017 and was FDA cleared in April 2018. The press release states that the Rain Sheath Transradial Introducer offers an ultra-low profile design, lubricious hydrophilic coating, and proprietary kink recovery technology that enables the sheath to maintain lumen patency throughout the procedure, even after a kink occurs. It also says that the RBL-TG and RBL-JK universal shapes build on the strong legacy of Cordis’ catheter technology, and that the Zephyr Band is designed to simplify how a physician closes the procedure.
Kevin Croce (Brigham and Women’s Hospital, Boston, USA) says: “It’s really exciting to have new and innovative tools to support complex radial revascularisation procedures for our patients. These improvements in sheath and catheter technologies will enable us to increase radial adoption in the USA so that we can maximise PCI success while minimising bleeding complications.”